Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann Rachel P.; Srimuninnimit Vichien; Bordonaro Roberto; Kavan Petr; Di Bartolomeo Maria; Maiello Evaristo; Cicin Irfan; Garcia-Alfonso Pilar; Chau Ian; Fedyanin Mikhail Y.; Fernandez Martos Carlos; Ter-Ovanesov Mikhail; Peeters Marc; Ko Yoo-Joung; Yalcin Suayib; Karthaus Meinolf; Aparicio Jorge; Heinemann Volker; Picard Pascaline; Bury Denise; Drea Edward; Sobrero Alberto

首页> 外文期刊>Clinical colorectal cancer >Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

【24h】

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

机译：Aflibercept Plus Folfiri用于转移性结直肠癌的二线治疗：来自全球AfliBercept安全和健康相关的生活质量计划（ASQOP）的观察

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.

机译：本研究评估了用AfliBercept和Folfiri（Fluorouracil，Leucovorin，Irinotecan）进行治疗的转移性结肠直肠癌患者的安全性和生活质量。大多数用这种组合治疗的患者在生活质量评分中经历了改善或稳定性。 AfliBibercept Plus folfiri可容许治疗转移性结肠直肠癌患者的安全性，类似于这些单独药物的先前研究中所见。

著录项

来源
《Clinical colorectal cancer》 |2019年第3期|共12页
作者
Riechelmann Rachel P.; Srimuninnimit Vichien; Bordonaro Roberto; Kavan Petr; Di Bartolomeo Maria; Maiello Evaristo; Cicin Irfan; Garcia-Alfonso Pilar; Chau Ian; Fedyanin Mikhail Y.; Fernandez Martos Carlos; Ter-Ovanesov Mikhail; Peeters Marc; Ko Yoo-Joung; Yalcin Suayib; Karthaus Meinolf; Aparicio Jorge; Heinemann Volker; Picard Pascaline; Bury Denise; Drea Edward; Sobrero Alberto;
展开▼
作者单位

Inst Canc Estado Sao Paulo Sao Paulo Brazil;

Siriraj Hosp Ramathibodi Hosp Bangkok Thailand;

Garibaldi Nesima Hosp Dept Oncol Catania Italy;

McGill Univ Jewish Gen Hosp Segal Canc Ctr Gerald Bronfman Dept Oncol Montreal PQ Canada;

Ist Nazl Tumori Fdn IRCCS Milan Italy;

IRCCS Casa Sollievo Sofferenza San Giovanni Rotondo Italy;

Trakya Univ Balkan Oncol Hosp Dept Internal Med Div Med Oncol Edirne Turkey;

Hosp Univ Gregorio Maranon Madrid Dept Med Oncol Madrid Spain;

Royal Marsden NHS Fdn Trust Gastrointestinal &

Lymphoma Unit Sutton Surrey England;

NN Blokhin Natl Med Res Ctr Oncol Dept Clin Pharmacol &

Chemotherapy Moscow Russia;

Inst Valenciano Oncol Dept Med Oncol Valencia Spain;

Clin Cent Hosp Presidential Adm Russian Federat Thoracoabdominal Oncosurg Dept Moscow Russia;

Antwerp Univ Hosp Dept Oncol Edegem Belgium;

Univ Toronto Sunnybrook Odette Canc Ctr Toronto ON Canada;

Hacettepe Univ Canc Inst Dept Med Oncol Ankara Turkey;

Stadt Klinikum Munchen Klinikum Neuperlach Munich Germany;

Hosp Univ &

Politecn Fe Valencia Spain;

Ludwig Maximilian Univ Munich Univ Hosp Grosshadern Dept Med Oncol Munich Germany;

Sanofi Paris France;

Sanofi Cambridge MA USA;

Sanofi Cambridge MA USA;

IRCCS Azienda Osped Univ San Martino Genoa Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Antiangiogenic; Colorectal neoplasms; Patient-reported outcome measures; Receptors; Vascular endothelial growth factor;

机译：抗炎;结直肠肿瘤;患者报告的结果措施;受体;血管内皮生长因子;

相似文献

外文文献
中文文献
专利

1. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP) [J] . Riechelmann Rachel P., Srimuninnimit Vichien, Bordonaro Roberto, Clinical colorectal cancer . 2019,第3期

机译：Aflibercept Plus Folfiri用于转移性结直肠癌的二线治疗：来自全球AfliBercept安全和健康相关的生活质量计划（ASQOP）的观察
2. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy [J] . Van Cutsem Eric, Joulain Florence, Hoff Paulo M., Targeted oncology . 2016,第3期

机译：Aflibercept Plus FOLFIRI与安慰剂Plus FOLFIRI在二线转移性结直肠癌中的关系：III期VELOR研究的生存率事后分析，分析排除了在完成基于奥沙利铂辅助治疗的患者中或治疗后6个月内复发的患者
3. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI plus Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer [J] . Pentheroudakis George, Kotoula Vassiliki, Koliou Georgia-Angeliki, Clinical colorectal cancer . 2018,第4期

机译：Amalthea：前瞻性，单臂研究Hellenic合作肿瘤组（HECOG）评估第一线Folfiri加上6个月的疗效和安全性，然后在转移性结肠直肠癌患者中进行AFLiBercept维护
4. Health-related Fitness in Colorectal Cancer Survivors: Changes over Treatment and Following Exercise Training. [D] . Sellar, Christopher Michael. 2011

机译：大肠癌幸存者的健康相关适应性：治疗和运动训练后的变化。
5. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer [O] . Hironaga Satake, Koji Ando, Eiji Oki, 2020

机译：努力研究议定书研究：对Folfoxiri加Bevacizumab的进展后的二线治疗或在不可切除/转移性结直肠癌患者的维持治疗期间对Folfiri加上的前瞻性研究
6. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer [O] . Hironaga Satake, Koji Ando, Eiji Oki, 2020

机译：努力研究议定书研究：对Folfoxiri加Bevacizumab的进展后的二线治疗或在不可切除/转移性结直肠癌患者的维持治疗期间，对Folfiri加上的前瞻性研究

Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

摘要

著录项

相似文献

相关主题

期刊订阅